NeRRe Therapeutics Ltd., which was spun out of GlaxoSmithKline PLC in 2012, is advancing a pipeline of neurokinin receptor antagonists through the clinic, and earlier this year raised £23m. CEO Dr Mary Kerr explains how the company plans to generate Phase II data on orvepitant, a chronic respiratory candidate; and to advance NT-814 as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.
NeRRe's products originated in GSK and were taken over when the UK big pharma decided to deprioritize neurosciences and spin...








